Navigation Links
Frost & Sullivan Commends Nycomed for Excellence in Product Differentiation Innovation
Date:3/23/2009

LONDON, March 23 /PRNewswire/ -- The "2008 European Tissue Sealants & Topical Hemostats Product Differentiation Innovation Award" is conferred on Nycomed in recognition of its revolutionary product - TachoSil. The innovative surgical patch, TachoSil is poised to be the future of the European tissue sealants and topical hemostats markets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

At present, Nycomed, with TachoSil, is the sole company in the market with a ready-to-use dual action patch. TachoSil is unique: it does not fit into any of the standard market segments and constitutes a separate category on its own.

"This pioneering product has both haemostatic and sealing properties and can be used to stop bleeding as well seal tissue," explains Frost & Sullivan Research Analyst Divya Belle. "TachoSil combines the bioactive mechanism of action of human coagulation factors fibrinogen and thrombin with a collagen patch for mechanical support."

TachoSil effectively fulfills the market need for an easy-to-use product with ready-to-use features. TachoSil is safely absorbed by the body within weeks after application. It can be stored at room temperature and is available in three different sized patches which require no preparation before surgical use. Additionally, it minimizes the risk of post-operative re-bleedings, reducing hospital stays and the need for re-operations.

Moreover, due to its strong hemostatic and sealing properties, TachoSil meets the need for products that are able to control bleeding and seal tissue during surgeries. Such multiple attributes have underlined the competitive edge enjoyed by TachoSil.

Most fibrin sealants or hemostats available in the market today are bovine-based. These products have attendant safety concerns related to the bovine protein Aprotinin or bovine thrombin which carries the risk of allergic reactions, autoimmune syndromes and transfer of diseases.

"With TachoSil, Nycomed has eliminated Aprotinin, offering a product that is free of bovine components," states Belle. "Accordingly, there is no risk of transmittance of bovine diseases since it contains only the coagulation factors - human fibrinogen and human thrombin."

TachoSil has been registering high growth rates of over 20 per cent. Testifying to its efficacy and potential for continued success is the recent agreement entered into by Nycomed with Baxter International, with the latter set to market and distribute the TachoSil patch in the United States, after approval.

The Frost & Sullivan Award for Product Differentiation Innovation is presented to the company that has best demonstrated the ability to develop and/or advance products with more innovative capabilities than competing vendors and products. This Award recognises the company's successful adoption of new or existing technology that has become a part of its well-designed product family. Such innovation is expected to significantly contribute to the industry in terms of product performance and degree/rate of technical change.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management.

Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of euro 3,4 billion and an adjusted EBITDA of euro 1,2 billion.

For more information visit www.nycomed.com

    Nycomed Contact Information

    Jorgen Persson
    International Marketing Unit Director
    Nycomed Group
    P.O. Box 88
    Langebjerg 1
    DK-4000 Roskilde, Denmark
    Direct Line: +45 46 77 10 57
    Mobile: +45 40 95 51 57
    Fax: +45 46 75 79 34
    E-mail: Joergen.Persson@nycomed.com
    www.nycomed.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

    Frost & Sullivan Contact Information
    Jasmine Malone - Promotions Coordinator
    Phone: 0044 207 915 7869
    E-Mail: jasmine.malone@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology: